Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25864483 | 0.88 | CA12 (0.31) | CA12CA1CA2CA9 | |
| SCHEMBL24769074 | 0.85 | CA12 (0.35) | CA12CA1CA2CA9MBOAT4 | |
| SCHEMBL25465743 | 0.81 | — | — | |
| SCHEMBL25464313 | 0.73 | CA12 (0.37) | CA12CA1CA2CA9 | |
| SCHEMBL23989933 | 0.73 | CA12 (0.36) | CA12CA1CA2CA9MBOAT4 | |
| SCHEMBL23989376 | 0.72 | MBOAT4 (0.39) | CA12CA1CA2CA9MBOAT4 | |
| SCHEMBL23989439 | 0.69 | CA12 (0.39) | CA12CA1CA2CA9MBOAT4 | |
| SCHEMBL25857698 | 0.67 | CA12 (0.44) | CA12CA1CA2CA9 | |
| SCHEMBL25745146 | 0.66 | CA12 (0.36) | CA12CA1CA2CA9MBOAT4 | |
| SCHEMBL13953040 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | CA12 4365/4885CA1 4571/4885CA2 3989/4885 |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | CA12 4365/4885CA1 4571/4885CA2 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.